Article Versions Notes

Deak-Mihaly D, Iluta S, Pasca S, Jitaru C, Roman A, Andries A, Padurariu-Covit M, Petrushev B, Vasilache A, Bojan A, et al. Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma. Journal of Clinical Medicine. 2021; 10(19):4483. https://doi.org/10.3390/jcm10194483

Deak-Mihaly, Dalma, Sabina Iluta, Sergiu Pasca, Ciprian Jitaru, Andrei Roman, Alexandra Andries, Monica Padurariu-Covit, Bobe Petrushev, Anca Vasilache, Anca Bojan, and et al. 2021. "Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma" Journal of Clinical Medicine 10, no. 19: 4483. https://doi.org/10.3390/jcm10194483

Deak-Mihaly, D., Iluta, S., Pasca, S., Jitaru, C., Roman, A., Andries, A., Padurariu-Covit, M., Petrushev, B., Vasilache, A., Bojan, A., Zdrenghea, M., Dascalescu, A., Antohe, I., Colita, A., Colita, A., Dima, D., Tanase, A., & Tomuleasa, C. (2021). Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma. Journal of Clinical Medicine, 10(19), 4483. https://doi.org/10.3390/jcm10194483